Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSN0402 in Healthy Volunteers
NCT06482190Phase 1Recruiting
- Sponsor
- Resproly
- Start
- Jul 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RSN0402 in idiopathic pulmonary fibrosis (IPF) (10 arms), sponsored by Resproly. Primary endpoints: Treatment Emergent Adverse Events (TEAEs) at Day 14, Changes in Physical Examination at Day 14 and 4 more. Started Jul 2024; status: recruiting.
02
Drugs
RSN0402
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT06482190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06482190.